

Abstract

This application relates to a method of separating the phosphate diastereoisomers of gemcitabine-[phenyl-benzoxo-L-alaninyl)]-phosphate (NUC-1031) using crystallisation. In particular, crystallisation from isopropyl alcohol provides gemcitabine[phenyl-benzoxo-L-alaninyl)]-(S)-phosphate in high diastereoisomerically pure form. This application also relates to a crystalline form of gemcitabine-[phenyl-benzoxo-L-alaninyl)]-(S)-phosphate.

[Figure 1]